#USA #Irvine #Relief Cardiovascular #Harry Rowland #Relief System

Relief Cardiovascular Appoints Harry Rowland as Chairman of the Board

On December 18, 2025, Relief Cardiovascular, a pioneering medical technology firm, announced the appointment of Harry Rowland as its new Chairman of the Board. Founded to revolutionize heart failure treatment, Relief Cardiovascular is at the forefront of innovation with its Relief System, a transcatheter implant that aims to intelligently manage cardiac preload to reduce congestion in heart failure patients.

Harry Rowland is noted for his role as the co-founder and CEO of Endotronix, a medical device enterprise recognized for its development of the Cordella™ Pulmonary Artery (PA) Sensor System. Under his leadership, Endotronix successfully navigated through various stages of product development, culminating in an acquisition by Edwards Lifesciences in 2024. This impressive accomplishment highlights Rowland's expertise in the medical device sector, particularly within heart failure management.

Alex Cooper, the current CEO of Relief Cardiovascular, expressed his enthusiasm about Rowland's appointment. He remarked, "Harry is a remarkable leader who guided Endotronix from napkin sketch to commercial approval and exit. His leadership experience, domain expertise, and understanding of the clinical and operational complexities of remote management make him an exceptional fit for Relief as we expand the Relief System into broader clinical evaluation. I'm excited to work alongside Harry – his guidance will accelerate our journey and strengthen our ability to deliver meaningful benefit to patients."

Rowland's insights into heart failure present a promising perspective for Relief Cardiovascular. He noted, "One of the most fundamental challenges in heart failure is controlling congestion. Relief's approach to drive decongestion while protecting the kidneys has the potential to address a critical need in heart failure care. I'm thrilled to support the company as it works to deliver a scalable and clinically meaningful solution for patients and clinicians battling heart failure congestion."

About Relief Cardiovascular

Relief Cardiovascular is a privately held entity committed to enhancing treatment outcomes for patients suffering from heart failure. The company has developed the Relief System, a smart transcatheter implant designed to alleviate congestion and foster improved outcomes by merging hemodynamic monitoring with active preload modulation. This innovative approach is a response to the staggering number of individuals affected by heart failure globally.

Inception of the company began within inQB8 Medical Technologies, LLC—an incubator dedicated to nurturing medical innovations. The launch of the Relief System was supported through a Series A financing round co-led by Broadview Ventures and Advent Life Sciences, alongside the backing of Good Growth Capital and Heartwork Capital, further solidifying the financial foundation needed to pursue their first-in-human studies.

As the company forges ahead, the leadership of Rowland is expected to usher in a new era of growth and technological advancement for Relief Cardiovascular. His rich experience in medical device innovations positions the company to tackle the ongoing challenges faced in heart failure management and embodies their mission to provide meaningful solutions for patients and healthcare providers alike.

This significant leadership change signals Relief Cardiovascular's commitment to enhancing clinical outcomes and addressing critical needs within the healthcare landscape. The horizon appears bright for the company as it aims to set new standards in heart failure treatment methodologies, fundamentally changing the way patients experience care for this complex condition.